Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis

Journal of Hepatology

Volumn 38, Issue 1, 2003, Pages 24-31

  Jalan, Rajiv ^a   Sen, Sambit ^a   Steiner, Christian ^a   Kapoor, Dharmesh ^a   Alisa, Akeel ^b   Williams, Roger ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CROMWELL HOSPITAL   (United Kingdom)

Author keywords

Albumin; Dialysis; Extracorporeal liver support; Molecular adsorbents recirculating system

Indexed keywords

ALBUMIN; BILIRUBIN; CREATININE;

ADULT; ALBUMIN DIALYSIS; ALCOHOL LIVER DISEASE; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DEVICE; DISEASE SEVERITY; FOLLOW UP; HEART OUTPUT; HEMODIALYSIS; HEMODYNAMIC MONITORING; HEPATIC ENCEPHALOPATHY; HUMAN; KIDNEY FUNCTION; MALE; MEAN ARTERIAL PRESSURE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK ASSESSMENT; SURVIVAL RATE; SYSTEMIC VASCULAR RESISTANCE; THROMBOCYTOPENIA;

ACUTE DISEASE; BILIRUBIN; BLOOD PRESSURE; CARDIAC OUTPUT; CREATININE; FEASIBILITY STUDIES; HEPATIC ENCEPHALOPATHY; HEPATITIS, ALCOHOLIC; HUMANS; MALE; MIDDLE AGED; PROTHROMBIN TIME; SEVERITY OF ILLNESS INDEX; SORPTION DETOXIFICATION; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; VASCULAR RESISTANCE;

EID: 0037230428     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00334-3     Document Type: Article

References (35)

1. Maddrey WC, Boitnott JK, Bedine MS, Weber Jr FL, Mezey E, White Jr RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75:193-199.
2. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649.
3. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-710.
4. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with endstage liver disease. Hepatology 2001;33:464-470.
5. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-829.
6. Zimmerman JE, Wagner DP, Seneff MG, Becket RB, Sun X, Knaus WA. Intensive care unit admissions with cirrhosis: risk-stratifying patient groups and predicting individual survival. Hepatology 1996;23:1393-1401.
7. Singh N, Gayowski T, Wagener MM, Marino IR. Outcome of patients with cirrhosis requiring intensive care unit support: prospective assessment of predictors of mortality. J Gastroenterol 1998;33:73-79.
8. Mathurin P, Mendenhall CL, Carithers RL, Ramond MJ, Maddrey WC, Garstide P, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002;36:480-487.
9. Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990;113:299-307.
10. Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: A meta-analysis adjusting for confounding variables. Gut 1995;37:113-118.
11. Christensen E. Alcoholic hepatitis - glucocorticosteroids or not? J Hepatol 2002;36:547-548.
12. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-1648.
13. Ellis AJ, Hughes RD, Wendon JA, Dunne J, Langley PG, Kelly JH, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996;24:1446-1451.
14. Detry O, Arkadopoulos N, Ting P, Kahaku E, Watanabe FD, Rozga J, et al. Clinical use of a bioartificial liver in the treatment of acetaminophen-induced fulminant hepatic failure. Am Surg 1999;65:934-938.
15. O'Grady JG, Gimson AE, O'Brien CJ, Pucknell A, Hughes RD, Williams R. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988;94:1186-1192.
16. Ash SR, Carr DJ, Blake DE, Rainier JB, Demetriou AA, Rozga J. Effect of sorbent-based dialytic therapy with the BioLogic-DT on an experimental model of hepatic failure. ASAIO J 1993;39:M675-M680.
17. Stange J, Mitzner S. A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patient's blood and a bioartificial liver. Int J Artif Organs 1996;19:677-691.
18. Stange J, Mitzner SR, Risler T, Erley CM, Lauchart W, Goehl H, et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999;23:319-330.
19. Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977;72:573-583.
20. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164-176.
21. Gines P, Arroyo V. Is there still a need for albumin infusions to treat patients with liver disease? Gut 2000;46:588-590.
22. Jalan R, Hayes PC. Hepatic encephalopathy and ascites. Lancet 1997;350:1309-1315.
23. Stange J, Mitzner SR, Klammt S, Freytag J, Peszynski P, Loock J, et al. Liver support by extracorporeal blood purification: a clinical observation. Liver Transpl 2000;6:603-613.
24. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:277-286.
25. Lee KH, Wendon J, Lee M, Da Costa M, Lim SG, Tan KC. Predicting the decrease of conjugated bilirubin with extracorporeal albumin dialysis MARS using the predialysis molar ratio of conjugated bilirubin to albumin. Liver Transpl 2002;8:591-593.
26. Lucey MR. Is liver transplantation an appropriate treatment for acute alcoholic hepatitis? J Hepatol 2002;36:829-831.
27. Curry S, Mandelkow H, Brick P, Franks N. Crystal structure of human seram albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Stract Biol 1998;5:827-835.
28. Bourdon E, Blache D. The importance of proteins in defence against oxidation. Antioxid Redox Signal 2001;3:293-311.
29. Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, Vita J, et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA 1992;89:7674-7677.
30. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991;337:776-778.
31. Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999;104:1223-1233.
32. Kapoor D, Williams R, Jalan R. MARS: a new treatment for hepatorenal failure. Molecular adsorbent and recirculating system. Gastroenterology 2000;119:1799-1800.
33. Schmidt LE, Svendsen LB, Sorensen VR, Hansen BA, Larsen FS. Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure. Liver Transpl 2001;7:709-712.
34. Jalan R, Williams R. Improvement in cerebral perfusion after MARS therapy: further clues about the pathogenesis of hepatic encephalopathy? Liver Transpl 2001;7:713-715.
35. Davenport A, Will EJ, Davidson AM. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 1993;21:328-338.